In particular, we are focused on hematologic disorders and cancer. Rigel is collaborating with Eli Lilly to develop Rigel’s RIPK1 inhibitors in immunological and neurodegenerative diseases. In addition, Rigel has an extensive portfolio of investigational agents being developed with our other partners. Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. These products are focused on the inhibition of select signaling pathways, including Axl tyrosine kinase (AXL) and murine double minute 2 (MDM2). Through strategic partnerships and collaborations, we are able to take advantage of additional experience and resources, while benefiting from the potential success of these future products, both through milestone payments and royalties.
South San Francisco, United States
Founded in 1996
101-250 Employees
Medium-Sized
Working industry
Biotechnology
Type of company
Educational institution, Manufacturer
Ownership structure
Public Company
Locations
1 Headquarter
Number of products
1 Product
Specialised areas
Therapeutics, Biotechnology, Pharmaceutical and Medicine Manufacturing, Pharmaceutical preparations Medical research, Chemical Manufacturing, Manufacturing, Pharmaceutical, Scientific Research and Development Services
Rigel Pharmaceuticals offers a wide range of products and services
Product
Products :: Rigel Pharmaceuticals, Inc. (RIGL)
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Rigel Pharmaceuticals operates in 1 country around the world
Get an overview of the locations of Rigel Pharmaceuticals
Location
Country
State
City
Headquarter
United States
California
South San Francisco
Some frequent questions that have been asked about Rigel Pharmaceuticals
Where is Rigel Pharmaceuticals located?
The company headquarter of Rigel Pharmaceuticals is located in South San Francisco, California, United States. It's worth noting, that the company may have more locations
How many employees does Rigel Pharmaceuticals approximately have?
As of the latest available information Rigel Pharmaceuticals has around 101-250 employees worldwide.
When was Rigel Pharmaceuticals founded?
Rigel Pharmaceuticals was founded in 1996
In which industries does Rigel Pharmaceuticals mainly work?
The company Rigel Pharmaceuticals has it's main focus in the industries of Biotechnology
What is the current company status of Rigel Pharmaceuticals?
Based on the founding year and the amount of employees the company Rigel Pharmaceuticals seems to be a Medium-Sized at the current state. Note that over time that status can change
Check out some interesting alternative companies to Rigel Pharmaceuticals
Revolution Medicines
Temecula, United States
101-250 Employees
2015
We are utilizing our deep understanding of genetic drivers and adaptive resistance mechanisms in cancer, coupled with robust drug discovery and medicinal chemistry capabilities, to build a portfolio of compounds that inhibit critical signaling nodes within the RAS and associated pathways, such as the mTOR pathway. Our cohesive approach of focusing on targets within these signaling pathways underpins our clinical strategy of exploring mechanism-based dosing paradigms and in-pathway combinations to optimize treatment for cancer patients. Our most advanced product candidate is RMC-4630, a clinical-stage drug candidate that potently and selectively inhibits SHP2, a central node in the RAS signaling pathway. In collaboration with our partner, Sanofi, we are evaluating RMC-4630 in a multi-cohort Phase 1/2 clinical program for a range of tumor types featuring specific oncogenic mutations. Additionally, we are developing a portfolio of mutant-selective RAS inhibitors that we believe are the first potent, selective, cell-active inhibitors of the active, GTP-bound form of RAS, or RAS(ON).
Redx Pharma
Macclesfield, United Kingdom
51-100 Employees
2010
We are building a leading biotechnology company through the development of novel and differentiated targeted medicines in cancer and fibrotic disease, and the emerging area of cancer-associated fibrosis, where we see the opportunity to be best-in-class, or first-in-class. Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted medicines for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. Our ambition is to create world leading medicines that will transform patients’ lives, by delivering better medicines faster. Deliver Focus our differentiated, targeted small molecules towards commercially attractive markets in which we believe we can be successful. At Redx, our ambition is to create world leading medicines that will transform patients’ lives, by delivering better medicines faster. The securities referred to herein may not be offered, sold, resold, taken up, transferred, delivered or distributed, directly or indirectly, within, into or in the United States of America or any US territory, Australia, Canada, Japan, the Republic of South Africa or any other Restricted Jurisdiction except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States or such other jurisdiction. There will be no public offer of securities in the United States or any other Restricted Jurisdiction. Zelasudil is a clinical stage, highly selective and orally available ROCK2 inhibitor being developed for the treatment of idiopathic pulmonary fibrosis and fibrotic diseases.
Rafael Holdings
Newark, United States
11-50 Employees
2017
The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd., and is seeking opportunities to invest, acquire or in-license additional therapeutic assets which address high unmet medical needs. Rafael Holdings, Inc., (NYSE: RFL) is a fast-growing company focused on the discovery and development of novel oncological therapeutics to improve and extend the lives of patients through a wholly-owned and controlled portfolio of companies. Rafael is committed to providing reasonable accommodations for qualified individuals with disabilities and disabled veterans in our job application procedures.
SignalRx Pharmaceuticals
Omaha, United States
- Employees
2012
SignalRx is a privately owned biopharmaceutical company, with operations in San Diego, California and Omaha, Nebraska, that is pioneering the development of a new class of effective cancer targeted therapeutics. We are committed to the development of oncology products that significantly improve the lives of pediatric and adult cancer patients. The founders of SignalRx are inventors of the second PI3K inhibitor to enter the clinic and are leaders capitalizing on selective multi-target single small-molecule drug design and development. SignalRx is pursuing unique programs targeting the combined inhibition of key pathways involved in cancer proliferation, metastasis, angiogenesis as well as immuno-oncology (e.g., BTK, BRD4, CDK, PI3K, MYC).
FibroGen
San Francisco, United States
251-500 Employees
1993
We are keenly focused on leveraging the body’s natural pathways to treat cancer and its related conditions. FibroGen and our partner AstraZeneca filed a supplemental new drug application with the China Health Authority for roxadustat in patients with chemotherapy-induced anemia and expect an approval decision in mid-2024. We are developing products with the potential to change lives. We are dedicated to responsibly developing groundbreaking therapies for serious and life-threatening diseases. We accelerate the delivery of innovative treatments that operate at the cutting edge of cancer research. Pamrevlumab is a potential first-in-class human monoclonal antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in proliferative disorders and certain cancer cell types. FG-3246 is a potential first-in-class fully human antibody-drug conjugate (ADC), in-licensed from Fortis and being developed with FibroGen for metastatic castration-resistant prostate cancer and other tumor types.
RIANA Therapeutics
Vienna, Austria
1-10 Employees
2023
We developed and protected a unique cell-based phenotypic screening system that faithfully allows screening for inhibitors to disrupt such PPI. We develop novel drugs against challenging protein-protein interactions to treat cancer using our proprietary phenotypic drug discovery platform. RIANA Therapeutics GmbH is a spin-off from University of Veterinary Medicine, Vienna founded in 2023 to exploit academic findings from the Moriggl lab and develop therapeutics for the cancer patients. Targeting such oncogenic PPI (e.g., oligomerization of STAT5B) is a novel, highly innovative approach toward the development of potent and safe medicines for the treatment of hematopoietic and other cancer types.